Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial by Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Get full text

ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response by Jing Wang, Lei Feng, Qi Wang, Erminia Massarelli, Renata Ferrarotto, Michael A Curran, Jack Lee, Ignacio Wistuba, Cornelis J M Melief, Bonnie S Glisson, Kimal Rajapakshe, Cristian Coarfa, William William, Luana Guimaraes de Sousa, Jaime Rodriguez Canales, Renee L Chin, Tomas Z Barrese, Faye M Johnson

Get full text

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch re... by Heather Lin, Vivek Subbiah, Siqing Fu, Aung Naing, Courtney Nicholas, Shubham Pant, Chad Tang, Michael A Curran, David S Hong, Ying Yuan, Sarina A Piha-Paul, Jordi Rodon Ahnert, Timonthy A Yap, Apostolia M Tsimberidou, Daniel D Karp, Anupallavi Srinivasamani, Coline Couillault, Genevieve P Hartley, James Dai, Ecaterina E Ileana Dumbrava, Paola Guerrero, Sarah Dhebat, Theresa Proia

Get full text